References
- Wirth D, To Bid or Not to Bid, That is the Question: The Assessment of Bidding Markets in Merger Control, https://corpgov.law.harvard.edu/2016/12/12/ to-bid-or-not-to-bid-that-is-the-question-theassessment-of-biddingmarkets- in-merger-control/
- Bird&Bird White Paper Public Procurement of Medicinal products, Common legislation but diverging implementation approaches throughout the EU. Ed. M Martens and N Carbonelle, downloaded from https://www.twobirds.com/~/ media/pdfs/white-papers/public-procurementof-medicinal-products.pdf, 16/8/2018
- Government wants action on competitive tendering for NHS’s support services, Br Med J (Clin Res Ed). 1983 Sep 17;287(6395):850
- Hessou P, Joint Bulk Purchasing of Essential Drugs, presentation at the WHO/WTO workshop on differential pricing and financing of essential drugs, Høsbjør 2001, available at https://www.wto.org/english/tratop_e/trips_e/ tn_hosbjor_e.htm [Accessed 18 August 2019].
- Lee MG, Henry GL., Drug availability in Jamaica, West Indian Med J. 1989 Jun;38(2):105-9
- World Health Organization, Operational principles for good pharmaceutical procurement, Geneva 1999, WHO/ EDM/PAR/99.5
- Cohen JC, Public Policies in the Pharmaceutical Sector: A Case Study of Brazil, LCSHD Paper Series No 2106
- Nico Bacharidis, Global Tender & Contracting Lead for Established Products at Pfizer, at the Market Access & Pricing Excellence 2015 Conference June 3 – 4, 2015, Amsterdam; https://social.eyeforpharma. com/market-access/making-tenders-work-globallypfizer-approach [Accessed 18 August 2019].
- ÖBIG Forschungs- und Planungsgesellschaft mbH Tendering of Pharmaceuticals in EU Member States and EEA countries Results from the country survey Final version June 2008 https://ppri.goeg.at/ Downloads/Publications/Final_Report_Tendering_ June_08.pdf [Accessed 18 August 2019].
- COMMISSION STAFF WORKING DOCUMENT IMPACT ASSESSMENT Accompanying the document Proposal for a DIRECTIVE OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of the national health insurance systems SWD(2012) 30 final https://eurlex.europa.eu/resource.html?uri=cellar:df38ace5- 37cf-435f-9691-9f58ec6a1c3e.0001.02/ DOC_1&format=PDF [Accessed 8 August 2019].
- Management Sciences for Health. Managing the tender process. In: Embrey M, Ryan M, editors. MDS-3: Managing Access to Medicines and Health Technologies. Arlington (VA): MSH; 2012:401–428
- Petrou, P and Talias MA, Price Determinants of the Tendering Process for Pharmaceuticals in the Cyprus Market, Value In Health Regional Issues 7c 2015: 67-73
- Curto S et al. Regional tenders on biosimilars in Italy: An empirical analysis of awarded prices. Health Policy 116; 2014: 182-187
- Kanavos P, Seeley L, Vandoros S. Tender Systems for Outpatient Pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. Brussels, Belgium: European Commission; 2009. Ref. Ares (2014) 3853545
- Seidman G, Atun R. Do changes to supply chains and procurement processes yield cost savings and improve availability of pharmaceuticals, vaccines or health products? A systematic review of evidence from low-income and middle-income countries. BMJ GlobalHealth 2017;2:e000243. doi:10.1136/bmjgh-2016-000243
- Kalantar-Zadeh K History of ErythropoiesisStimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology A m J Nephrol 2017;45:235–247
- InfoService BiotechnologieNovember 22, 2012, Sales of recombinant drugs http:// www.i-s-b.org/sales-ofrecombinant-drugs/ accessed [Accessed 22 August 2019].
- See respective summaries of product characteristics
- Veys N, Dhondt A, Lameire N Pain at the injection site of subcutaneously administered erythropoietin: phosphatebuffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol. 1998 Jan;49(1):41-4
- Storring PL et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol. 1998 Jan;100(1):79-89
- Yilmaz G et al. Tracking the Aftermath of a Corporate Scandal from a Network Perspective: The Case of Roche in Turkey, in Amjad Hadjikhani, Ulf Elg, Pervez Ghauri (ed.) Business, Society and Politics (International Business and Management, Volume 28) Emerald Group Publishing Limited, 2012, pp.303 – 325
- Mack A. Norway, biosimilars in different funding system. What works? Generics and Bio-similars Initiative Journal (GaBI Journal). 2015;4(2):90-2. [Accessed 29 July 2019].
- Levêque D. [Biosimilar drugs in oncology]. [Article in French]. Bull Cancer. 2016 Mar;103(3):294-8
- Leopold C, Habl C, Vogler S. Tendering of Pharmaceuticals in EU Member States and EEA countries Results from the country survey Final version June 2008. ÖBIG Forschungsund Planungsgesellschaft mbH available online at https://ppri.goeg.at/Downloads/ Publications/Final_Report_Tendering_ June_08.pdf [Accessed 15 July 2019].
- Dranitsaris G et al. Drug tendering: drug supply and shortage implications for the uptake of biosimilars. ClinicoEconomics and Outcomes Research 2017:9 573–584
- MacKay P, Is PHARMAC’s sole supply tendering policy harming the health of New Zealanders? J N Z Med Assoc (2005) 118;1214 Available at: http:// journal.nzma.org.nz/journal/118-1214/1433/; and the Pharmaceutical Management Agency Annual Report for the year ended 30 June 2010. Available at: http://www.pharmac.govt.nz/AnnualReport
- Department of Health & Social Care Investigation into NHS spending on generic medicines in primary care June 4, 2018 available at https:// www.nao.org.uk/wp-content/uploads/2018/06/ Investigation-into-NHS-spending-ongenericmedicines-in-primary-care.pdf
- Dave CV et al. High Generic Drug Prices and Market Competition: A Retrospective Cohort Study. Ann Intern Med. 2017 Aug 1;167(3):145-151
- Elsevier clinical solutions white paper: The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain, downloaded from http:// www.ncpa.co/pdf/elsevier_wp_genericdrug. pdf [Accessed 27 August 2019].
- Southey F. Shortages and soaring generic prices prompt US hospitals to form not-for-profit drug business 25-Jan-2018 https://www.Inpharmatechnologist.Com/article/2018/01/25/ shortages-andsoaring-generic-prices-prompt-ushospitals-to-form-not-for-profit-drug-business
- Pharmaceutical tenders by South African National Department of Health, see http://www.health.gov. za/tender/index1.php [Accessed 27 August 2019].
- Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy. 2011;101:146–152.
- EuropaBio White Paper on Public Procurement of Biological Medicines, June 2015, downloaded from
- For example: Neulasta® Onpro®, an administration device that injects pegfilgrastim 24 hours after installation
- In the European Pricing Platform congress in Lausanne, May 2014, participants were asked if net profit was a Key Performance Indicator for tendering people. Only one out of 40 attending companies had set its internal incentives on profit.
- Personal communication from the CEO of an Irish generic producer
